Who are Omalizumab for injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gallium Oxydatum, Columvi, Elrexfio, Elrexfio, Pluvicto, Lunsumio.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/omalizumab-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Omalizumab for injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Omalizumab for injection (Omalizumab for injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Immunology.

phase 3 Monoclonal antibody IgE Immunology Biologic Live · refreshed every 30 min

Target snapshot

Omalizumab for injection (Omalizumab for injection) — CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Omalizumab is a monoclonal antibody that targets the IgE molecule, preventing it from binding to its receptor on mast cells and basophils.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Omalizumab for injection TARGET	Omalizumab for injection	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	phase 3	Monoclonal antibody	IgE
Gallium Oxydatum	GALLIUM	Novartis	marketed		Glutamate carboxypeptidase 2, Prostate-specific antigen	2025-01-01
Columvi	glofitamab	Roche	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	B-lymphocyte antigen CD20	2023-01-01
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Pluvicto	Lutetium (177Lu) vipivotide tetraxetan	Aaa Usa Novartis	marketed	Radioligand Therapeutic Agent [EPC]	Prostate-specific antigen	2022-01-01
Lunsumio	MOSUNETUZUMAB	Roche	marketed		B-lymphocyte antigen CD20	2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-08-15 — Pluvicto · 10406240 · US
2028-08-15 — Pluvicto · 11318121 · US
2034-10-17 — Pluvicto · 10398791 · US

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Omalizumab for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/omalizumab-for-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing